Peripheral Arterial Disease – Landscape & Forecast – Disease Landscape & Forecast
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis that most often affects the arteries in the lower extremities. This condition is a major marker for more-serious systemic ischemic events, such as stroke and myocardial infarction. Because many patients are asymptomatic, PAD is underdiagnosed and undertreated. However, there is growing recognition that optimal management of PAD requires aggressive secondary prevention measures. PAD treatment is dominated by well-established generic drugs, restricting overall market value; however, novel emerging therapies, such as stem cell treatments, could significantly boost sales. Overall, the increasing number of prevalent cases, combined with the substantial unmet need, makes the treatment of PAD a high-growth market opportunity.
QUESTIONS ANSWERED
- A substantial gap exists in the treatment of PAD: a considerable percentage of patients remain undiagnosed and untreated. How do thought leaders believe this treatment gap can be reduced?
- What are the key pharmacotherapies used for PAD? What are the major unmet needs, according to thought leaders?
- How active is R&D for PAD? What are thought leaders’ opinions of novel therapies in development?
- How will the PAD therapy market grow with the emergence of new branded therapies, and how will these agents impact treatment practice?
CONTENT HIGHLIGHTS
- Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 20 country-specific interviews with thought-leading PAD experts. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of PAD by country, segmented by disease severity and diagnosed and drug-treated populations.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key PAD therapies through 2030, segmented by brands / generics and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Peripheral Arterial Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Key Findings
- Market Outlook
- Key Findings
- Market Drivers and Constraints
- What Factors Are Driving the Market for Peripheral Arterial Disease?
- What Factors Are Constraining the Market for Peripheral Arterial Disease?
- Sales of Peripheral Arterial Disease Therapies in the Major Pharmaceutical Markets: 2020-2030
- Patient Share of Peripheral Arterial Disease Therapies in the Major Pharmaceutical Markets: 2020-2030
- Drug-Class-Specific Trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key Findings
- Treatment Goals
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Peripheral Arterial Disease
- Current Treatments Used for Peripheral Arterial Disease
- Market Events Impacting the Use of Key Current Therapies for Peripheral Arterial Disease
- Antiplatelet Agents
- Thrombin Receptor Antagonists
- Anticoagulant Agents
- Lipid-Lowering Therapies
- ACL Inhibitors
- ACE Inhibitors and ARBs
- Beta Blockers
- Calcium Channel Blockers
- Vasoactive Therapies
- Prostaglandin Analogues
- Angiogenic Gene Therapies
- Nonpharmacological Approaches
- Medical Practice
- Key Findings
- Unmet Need Overview
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Shambhavi Shukla, M.Tech., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Ms. Shukla has authored competitive landscape and market insight reports on type 1 and type 2 diabetes, osteoporosis, and FSGS. Before joining Clarivate, she was with Evalueserve, where she worked closely with top pharmaceutical companies, helping them with commercial and technical ad-hoc requests. She holds a master’s degree in biotechnology from Amity University in India.